| Market Capitalization (Millions $) |
966 |
| Shares
Outstanding (Millions) |
84 |
| Employees |
117 |
| Revenues (TTM) (Millions $) |
56 |
| Net Income (TTM) (Millions $) |
-208 |
| Cash Flow (TTM) (Millions $) |
26 |
| Capital Exp. (TTM) (Millions $) |
10 |
Nurix Therapeutics Inc
Nurix Therapeutics Inc is a biopharmaceutical company that specializes in developing targeted protein modulation drugs for the treatment of various diseases. The company was founded in 2013, and is headquartered in San Francisco, California.
Nurix's technology platform is based on the discovery and understanding of the ubiquitin proteasome system (UPS), a naturally occurring biological process that regulates the degradation and recycling of proteins in cells. The company's approach involves using small molecule drugs to precisely target proteins within the UPS, thereby treating diseases at their root cause.
Nurix's research and development programs are focused on two key areas: oncology and immunology. Within oncology, the company is developing drugs to target specific cancer-causing genes, with the goal of creating more effective and targeted cancer therapies. In immunology, the company is developing drugs to treat inflammatory diseases, such as autoimmune disorders and graft-versus-host disease.
One of Nurix's most promising drug candidates is NX-2127, a small molecule drug designed to degrade the protein BCL-6, which is involved in the development of several types of lymphoma. The company has completed preclinical studies on NX-2127, and is currently advancing the drug into Phase 1 clinical trials.
Nurix has partnerships and collaborations with several major pharmaceutical companies, including Gilead Sciences, Eli Lilly, and Sanofi. These collaborations allow Nurix to leverage its expertise in protein modulation to develop new therapies in areas such as oncology, immunology, and neurology.
Overall, Nurix Therapeutics Inc is a cutting-edge biopharmaceutical company that is revolutionizing the treatment of diseases through its innovative protein modulation technology platform. With a focus on oncology and immunology, the company is well-positioned to make a significant impact on the healthcare industry in the years to come.
Company Address: 1700 Owens Street San Francisco 94158 CA
Company Phone Number: 660-5320 Stock Exchange / Ticker: NASDAQ NRIX
|
5.55%